SageView Advisory Group’s Mereo BioPharma MREO Stock Holding History

SageView Advisory Group’s Portfolio MREO Stock Details MREO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-161	Closed	-$68	–	1738
2025 Q4	$68	Buy	+161	New	+$306	﹤0.01%	2557

Other funds holding MREO

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return

SageView Advisory Group's MREO Position: Q1 2026 in Review

SageView Advisory Group sold out of Mereo BioPharma (MREO) in Q1 2026, closing a stake of 161 shares — an estimated $68 sold.

SageView Advisory Group first reported a position in MREO in Q4 2025 and held it in 1 quarter. The position peaked at $68 in Q4 2025. 63 funds tracked by Wall St. Rank hold MREO as of Q1 2026.

SageView Advisory Group reported no remaining Mereo BioPharma position as of Q1 2026 after selling out during the quarter.
SageView Advisory Group sold 161 Mereo BioPharma shares in Q1 2026, an estimated $68.
SageView Advisory Group first reported a position in Mereo BioPharma in Q4 2025 and held it in 1 quarter.
SageView Advisory Group's Mereo BioPharma position peaked at $68 in Q4 2025.
63 funds tracked by Wall St. Rank held Mereo BioPharma as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.